Immunoassay of Bromocriptine and Specificity of Antibody: Criteria for Choice of Antiserum and Marker Compound

  • J. Rosenthaler
  • H. Munzer
  • R. Voges
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 12)


To develop an assay for bromocriptine (2-bromo- α-ergokryptine), different hapten compounds were used to produce various animal antisera. Since all these were predominantly specific to the tricyclic peptide moiety of bromocriptine, the affinity constant Kwas considered a sufficient criterion for selecting a high energy antibody. The K value for the favoured antiserum (#270979) was 0.9 x 10 9 1/M. With the favoured tracer ligand, a detection limit of 0.17 ng/ml was achieved for bromocriptine in equilibrium with its epimer bromocriptinine. Metabolites such as the 8′-hydroxy derivative show virtually no cross-reaction.


Ergot Alkaloid Lysergic Acid Methane Sulphonate Tracer Compound High Specific Radioactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weber, H.P. (1980) in Ergot Compounds and Brain Function [VoL 23, Adv. Biochem. Psychopharmacol] (Goldstein, M., Calne, D.B., Lieberman, A. & Thorner, M.O., eds.) , Raven Press, New York, pp. 25–34.Google Scholar
  2. 2.
    Flückiger, E. & Wagner, H.-R. (1968)Experientia24, 1130.Google Scholar
  3. 3.
    Hökfelt, T. & Fuxe, K. (1972) in Brain-Endocrine Interaction (Knigge, K.M., Scott, D.E. & Weindl, A., eds.) , Karger, Basel, pp. 181–223.Google Scholar
  4. 4.
    Calne, D.B., Teychenne, P.F., Claveria, LE., Eastman, R., Greenacre, J.K. & Petrie, A. (1974)Br. Med. J. 4, 442–444CrossRefGoogle Scholar
  5. 5.
    Yalow, R.S. & Berson, S.A. (1971) In Competitive Protein Binding Assays (Odell, W.D. & Daughaday, W.H., eds.) , Lippincott, Philadelphia, pp. 1–21.Google Scholar
  6. 6.
    Levy, A., Kawashima, K. & Spector, S. (1976)Life Sci. 19, 1421–1429.CrossRefGoogle Scholar
  7. 7.
    Rosenthaler, J. & Munzer, H. (1976)Experientia32, 234–235.CrossRefGoogle Scholar
  8. 8.
    Rosenthaler, J., Nimmerfall, F., Sigrist, R. & Munzer, H. (1977)Eur. J. Biochem. 80, 603–609.CrossRefGoogle Scholar
  9. 9.
    Rosenthaler, J., Pacha, W.L., Koeberle, S. & Beveridge, T. (1980) in Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies (Usdin, E., Eckert, H. & Forrest, I.S., ) Elsevier/North Holland, New York, pp. 121–124Google Scholar
  10. 10.
    Eckert, H., Kiechel, J.R., Rosenthaler, J., Schmidt, R. & Schreier, E. (1978) in Ergot Alkaloids and Related Compounds, Vol. 49, Handbook of Experimental Pharmacology (Berde, B. & Schild, H.O., eds.) Springer-Verlag, Berlin, pp. 780–782.Google Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • J. Rosenthaler
    • 1
  • H. Munzer
    • 1
  • R. Voges
    • 1
  1. 1.Biopharmaceutical DepartmentSandoz Ltd.BasleSwitzerland

Personalised recommendations